-
GSH and GSSG Assay Kit for Hypoxic Tumors
2026-10-01
Learn how the GSH and GSSG Assay Kit supports reduced glutathione detection in hypoxic tumor models. This guide connects paired GSH/GSSG measurements with sample handling, immunometabolism, and defensible redox state analysis.
-
SIRT1, Mitochondrial Biogenesis, and Prion Toxicity
2026-10-01
Zhao and colleagues show that prion peptide toxicity in N2a cells is associated with reduced SIRT1 abundance and activity, impaired mitochondrial biogenesis, and mitochondrial dysfunction. Their experiments position the SIRT1–PGC-1α–TFAM axis as a mechanistic link between mitochondrial quality control and apoptosis, while identifying resveratrol as an experimental activator of this pathway.
-
AG-126: ERK Signaling in Neuroinflammation
2026-09-30
Explore how AG-126 and Tyrphostin AG-126 can help separate ERK1/2-dependent signaling from cell-type and circuit mechanisms in neuroinflammation research. This article translates inflammatory model evidence and a new striatal autism study into a cautious, causally oriented assay strategy.
-
WP1066: Cell-Permeable JAK2/STAT3 Inhibitor
2026-09-30
WP1066 is a cell-permeable JAK2/STAT3 inhibitor that suppresses phosphorylation-dependent signaling in cancer research models. Product information supports applications in renal carcinoma, acute myeloid leukemia, cancer cell proliferation assays, and pathway-focused pharmacology, while recent biomaterial research shows that activating—not inhibiting—JAK2/STAT3 can support macrophage-mediated bone repair.
-
Lambda Protein Phosphatase in BMAL1 Assays
2026-09-29
Lambda Protein Phosphatase provides a controlled way to test whether BMAL1 phosphorylation contributes to phase separation and circadian transcription. This guide presents a causal assay framework that goes beyond descriptive condensate imaging and strengthens phosphorylation site validation.
-
Carrier-Platin and the Intracellular ROS Storm
2026-09-29
Liu et al. describe carrier-platin, a polymer-confined platinum nanotherapeutic that produces a rapid intracellular ROS burst and kills cancer cells independently of DNA damage, apoptosis, or ferroptosis. The study provides a framework for evaluating ROS-generating chemotherapy against resistant tumors while highlighting the need to distinguish oxidative injury from specific regulated cell-death programs.
-
Gepotidacin Phase I PK, Safety, and Tolerability
2026-09-28
Three phase I studies characterized the pharmacokinetics, safety, and tolerability of gepotidacin (GSK2140944) after single or repeated oral dosing in healthy adults and older participants. The findings describe dose-proportional exposure, attainment of steady state, and tolerability across the tested regimens, providing a clinical pharmacology foundation for subsequent investigation.
-
Dual SORT LNPs for Multi-Organ Base Editing
2026-09-27
This study pairs organ-selective lipid nanoparticles to deliver base editors to the liver and lung in a preclinical model of alpha-1 antitrypsin deficiency. The approach achieved measurable PiZ correction in both tissues and improved disease-related readouts, while leaving human translation and long-term safety to be established.
-
Bleomycin Sulfate: Reading Fibrosis Models
2026-09-26
Bleomycin Sulfate can model DNA injury, but interpreting fibrosis requires separating initial damage from the cellular programs that build scar tissue. This article connects a recent TUG1–miR-30–SNAI2 study to practical choices in dermal fibrosis assays—and clarifies where pulmonary and cancer models differ.
-
Gepotidacin: Linking Target Activity to Exposure
2026-09-26
Explore how Gepotidacin’s distinct topoisomerase mechanism and human pharmacokinetic findings can inform more interpretable antibacterial assays. This perspective connects biochemical target engagement with exposure-aware research design while clarifying the limits of translating laboratory results.
-
Taltirelin Acetate: Assay Design for Reliable Results
2026-09-25
Learn how to use Taltirelin acetate (SKU C8755) thoughtfully in cell-based neuroprotection and Parkinson’s disease research. This scenario-driven guide covers concentration selection, assay controls, interpretation, handling, and practical product-selection criteria without treating one endpoint or model as universally predictive.
-
Multiplex PBMC Assay for Immunomodulator Screening
2026-09-25
Brox and Hackstein describe a human PBMC flow-cytometry assay that measures T-cell proliferation and activation alongside B-cell costimulatory responses. Its multiparametric readouts, Z-factor-based validation, and 295-compound pilot screen offer a practical framework for distinguishing immunomodulatory profiles while keeping primary-cell context.
-
Hoechst 33342 for TNT Transport Imaging Workflows
2026-09-24
Use Hoechst 33342 to add nuclear and cell-boundary context to live-cell studies of lipid-droplet transport through tunneling nanotubes—without mistaking a nuclear stain for a cargo or force reporter. This workflow pairs practical staining guidance with the optical-trapping findings that explain what a complementary nuclear channel can, and cannot, reveal.
-
Eudragit-Coated LNPs for Oral RNA Delivery
2026-09-24
Haque, Shrestha, and Mattheolabakis investigated whether a pH-sensitive Eudragit S 100 coating could protect lipid nanoparticles and their RNA cargo during gastrointestinal transit. The in vitro results support a formulation strategy for oral RNA delivery, while leaving in vivo absorption and efficacy to be established.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-23
Gu et al. show that CDK4/6 inhibition can restrain pancreatic tumor cell proliferation while simultaneously enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition as a complementary strategy that restores antitumor activity through coordinated regulation of GSK3β-mediated Wnt/β-catenin signaling and TGF-β/Smad pathway crosstalk.